The recent successes of immunotherapy have shifted the paradigm in cancer treatment, but because only a percentage of patients are responsive to immunotherapy, it is imperative to identify factors impacting outcome. Obesity is reaching pandemic proportions and is a major risk factor for certain malignancies, but the impact of obesity on immune responses, in general and in cancer immunotherapy, is poorly understood. Here, we demonstrate, across multiple species and tumor models, that obesity results in increased immune aging, tumor progression and PD-1-mediated T cell dysfunction which is driven, at least in part, by leptin. However, obesity is also associated with increased efficacy of PD-1/PD-L1 blockade in both tumor-bearing mice and clinical cancer patients. These findings advance our understanding of obesity-induced immune dysfunction and its consequences in cancer and highlight obesity as a biomarker for some cancer immunotherapies. These data indicate a paradoxical impact of obesity on cancer. There is heightened immune dysfunction and tumor progression but also greater anti-tumor efficacy and survival after checkpoint blockade which directly targets some of the pathways activated in obesity.
R ecent advances in our understanding of the mechanisms of immune regulation have led to major clinical breakthroughs in cancer, including the use of inhibitors of the PD-1/PD-L1 (PD-(L)1) axis, or 'checkpoint blockade' [1] [2] [3] . PD-(L)1 signaling is central to both initial T cell priming and later T cell exhaustion, which occurs with aging or chronic antigen stimulation resulting in impairment of proliferative and functional abilities 4 . Blockade of this pathway markedly augments T cell responses in a variety of viral and cancer models [5] [6] [7] [8] . However, despite the success of PD-(L)1 blockade in multiple malignancies, including melanoma and lung, renal and bladder cancer, these therapies fail to generate sustained benefits in most patients. Extensive efforts are underway to elucidate biomarkers and mechanisms of response 9 . Many studies have focused on the tumor microenvironment (TME) as well as mutational or antigenic load, but patient-associated factors such as sex, age, body mass index (BMI) and immunological history (for example, pathogen exposure) are also likely to profoundly impact immune responses and yet are poorly understood.
Obesity, defined by increased BMI (≥ 30 kg/m 2 ), reflecting visceral fat accumulation 10 , is reaching pandemic proportions. Obesity has been associated with numerous comorbidities such as diabetes, heart disease and cancer [10] [11] [12] and represents a significant societal burden accounting for > 20% of the total annual US healthcare expenditure 13 . Although obesity is characterized by a 'metainflammatory' state with dysregulated immune responses and 'inflammaging' 12 , little is understood about the impact of obesity on immune responses during cancer progression and immunotherapy. This is confounded by the use, in most preclinical cancer models, of young lean mice that fail to recapitulate the clinical scenario of elderly patients with cancer. Surprisingly, recent clinical analyses demonstrate that obesity is associated with improved response and survival of patients with cancer treated with targeted therapy and checkpoint blockade immunotherapy, although a mechanistic link was not elucidated 14, 15 . In this study, we investigated the impact of obesity on T cell responses and demonstrate a significant impact of obesity on the PD-(L)1 axis, immune aging and dysfunction across multiple species and cancer models. In particular, we demonstrate a marked effect of obesity on tumor progression in mice as well as on clinical outcomes in patients with cancer treated with PD-(L)1 checkpoint blockade stratified by body mass. These studies highlight the contrasting and paradoxical effects, both positive and negative, of obesity on cancer immune responses in the context of immunotherapy.
Results
Obesity-related T cell dysfunction across multiple species. We investigated T cell phenotype and function in control-diet mice (control, 10%-fat diet) versus diet-induced obese mice (DIO, 60%-fat diet) at 6 months ( Supplementary Fig. 1a -g) and 11-12 months (Fig. 1a-f and Supplementary Figs. 2 and 3 ) of age. DIO mice had a marked increase in subcutaneous and visceral adipose tissue, as demonstrated by magnetic resonance imaging ( Supplementary Fig. 1a,b) . Nonfasting glucose and hemoglobin A1c levels were within normal limits in both DIO and control mice ( Supplementary Figs. 1c,d and 2a ). At 6 months of age, DIO mice had an increased frequency of PD-1 + T cells in the liver ( Supplementary Fig. 1f ,g). By 11-12 months of age, DIO mice exhibited a significant increase in dysfunctional exhausted T cells in peripheral blood, liver and spleen. Specifically, DIO mice had an increase in the frequency of memory T cells in the peripheral blood ( Supplementary Fig. 2b ) and liver ( Fig. 1b ). Further analysis showed a > 2-fold increase in PD-1 expression in DIO versus control T cells ( Fig. 1c and Supplementary Fig. 2c ). Similar results were seen when examining CD4 + and CD8 + T cell subsets in 6 and 11-to 12-month-old mice (Supplementary Figs. 1f,g and 2d,e). To determine whether increased PD-1 expression in DIO mice was indicative of T cell dysfunction, we examined hallmarks of exhaustion, including diminished proliferative function and cytokine production. Ex-vivo stimulated polyclonal T cells from DIO mice demonstrated reduced proliferative capacity as well as reduced interferon-γ (IFN-γ ) and tumor necrosis factor-α (TNF-α ) production compared with control ( Fig. 1d-f ), and, again, similar results were seen when examining CD4 + and CD8 + T cell subsets ( Supplementary Fig. 3 ). We next assessed the impact of obesity in outbred non-human primates (NHPs, rhesus macaques (Macaca mulatta)) and humans and observed a remarkably similar pattern. T cells from spontaneously obese NHPs demonstrated a significant increase in the memory pool and PD-1 expression while also showing reduced proliferative capacity compared with nonobese NHPs (Fig. 1g,h and Supplementary Fig. 4a-f ). Healthy human volunteers were categorized into obese (BMI ≥ 30) and nonobese (BMI < 30) cohorts ( Supplementary Fig. 4g and Supplementary Table 1 ). T cells from these obese donors also demonstrated a significant increase in PD-1 expression and decreased proliferative function compared with nonobese donors (Fig. 1i,j) . Thus, across multiple species, we observed increased T cell exhaustion and dysfunction in obese subjects, providing novel data to support an obesity-associated phenotype of immune dysfunction.
Obesity promotes tumor growth and T cell exhaustion. We next studied the consequences of obesity on tumor immunity. A confounding issue in preclinical cancer modeling is the direct impact that obesity has on tumor growth kinetics 16 , which may obscure the effects of obesity on the immune response to the tumor. B16 melanoma tumors grew significantly faster in 6-month old DIO mice compared with control counterparts ( Fig. 2a and Supplementary  Fig. 5a ). Tumors in DIO mice exhibited increased metabolic activity as demonstrated by increased [ 18 F]fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET)/computed tomography (CT) scans ( Fig. 2b and Supplementary Fig. 5b ). We observed greater ulceration, necrosis, and invasion into subcutaneous fat by melanoma tumors in DIO mice ( Supplementary Fig. 5c ). Consistent with our previous findings in non-tumor-bearing mice, T cells in the TME of DIO mice demonstrated features of exhaustion. Specifically, DIO mice had a significantly higher frequency of tumor-infiltrating CD8 + T cells (CD8 + TILs) expressing PD-1, Tim3 and Lag3 and lower proliferation by Ki67 compared to control mice, as assessed by flow cytometry (Fig. 2c-f and Supplementary Fig. 5d ). Because regulatory T cells (T regs ) play a role in the TME and have been noted to be altered in obesity 17 , we also examined T regs in the TME. We did not observe differences in the frequency of T regs between DIO and control mice ( Supplementary Fig. 5e ), nor was there a difference in PD-L1 expression in the TME ( Supplementary Fig. 5f ). Interestingly, Cpt1a gene expression, a master regulator of fatty acid oxidation, was upregulated in both tumors and CD8 + T cells of DIO mice ( Supplementary Fig. 5g ). Cpt1a was recently identified as being upregulated in early-stage exhausted T cells after lymphocytic choriomeningitis virus infection and has been suggested to be a potential driver of the metabolic changes leading to exhaustion 18 . We observed similar results with 4T1 breast carcinoma cells in DIO BALB/c mice in terms of tumor growth ( Supplementary Fig. 5h -j) and TIL PD-1 expression ( Fig. 2g ), demonstrating these phenomena across strains and tumor types.
In addition to differences in the TME, the frequency of PD-1 + T cells was significantly increased systemically in the liver, spleen, and draining lymph nodes of tumor-bearing DIO mice ( Supplementary  Fig. 6 ). This finding is in contrast to non-tumor-bearing 6-monthold DIO mice, in which differences were observed only in the liver ( Supplementary Fig. 1 ), indicating that tumor challenge accelerated the exhaustion phenotype in 6-month-old DIO mice inducing an exhausted systemic phenotype resembling 11-to 12-month-old DIO mice. This coincided with a higher expression of transcription factor Eomes and a lower expression of T-bet on PD-1 + CD8 + T cells in liver, spleen, and draining lymph nodes of 6-month-old tumorbearing DIO mice compared to age-matched tumor-bearing controls ( Supplementary Fig. 6c ,e,g,h). Elevated expression of Eomes and decreased levels of T-bet are well-known markers of T cell exhaustion [19] [20] [21] . We observed the frequency of PD-1 + T cells in the visceral fat to be generally higher than that in other organs ( Supplementary  Fig. 6i -j), which is in agreement with recent reports 22 .
We next defined the molecular differences between sorted (> 95% purity) CD8 + memory T cells from the spleens and lymph nodes of B16-bearing control and DIO mice using transcriptomic analysis. Categorical clustering adjusted from previously described canonical T cell exhaustion and effector markers 23 corroborated the results of our tumor T cell phenotyping, demonstrating upregulation of exhaustion-related transcripts and downregulation of effector-related transcripts in T cells from DIO mice ( Fig. 2h) . Differential profile analysis also demonstrated marked global transcriptional differences of CD8 + T cells from control versus DIO mice ( Supplementary Fig. 7a ). This functional categorical clustering of markers was generated based on previously published data 24 . T cells from tumor-bearing DIO mice upregulated anergy-, senescence-, and TGF-β -associated genes as well as genes previously associated with obesity, diabetes and insulin resistance 22 ( Supplementary Fig. 7a ).
Using ontology and network analysis, we further observed global, log-fold differences in T cell gene expression from DIO versus control mice in genes involved in metabolism, T cell activation, Tolllike receptor signaling, regulation of chemotaxis and protein folding similarly ( Fig. 2i , Benjamini--Hochberg false discovery rate < 0.05). Similar results were obtained using represented ontologies of either down-regulated ( Fig. 2j ) or up-regulated ( Supplementary Fig.7b ) genes through network analysis. These results suggest that T cells from tumor-bearing DIO mice exhibit a transcriptomic profile that is markedly different from that of T cells from tumor-bearing control mice, consistent with increased exhaustion and inflammation.
Leptin levels are correlated with PD-1 expression. Obesity has been demonstrated to induce a metainflammatory state with increased proinflammatory cytokines, such as TNFα and IL-6, as well as elevated levels of glucose, insulin, fatty acids and leptin. Leptin, which is characteristically present at high levels in obesity, has not been previously linked to PD-1 expression, but studies suggest that it can affect T cell function [25] [26] [27] . The RNA sequencing (RNA-seq) analysis on T cells from B16-bearing control and DIO mice revealed differential expression of pathways involved in fat metabolism and T cell signaling and showed marked changes in the expression of genes previously described to be involved with leptin signaling 28 , including several IFN-inducible GTPases 29 ( Supplementary Fig. 8a ). In healthy human volunteers ( Supplementary Table 1 ), we observed significantly increased serum leptin levels in obese donors (Fig. 3a) , which correlated with PD-1 expression on CD8 + T cells ( Fig. 3b and Supplementary Fig. 8b) . Similarly, leptin levels were elevated in DIO mice, and this corresponded with an elevated frequency of PD-1 on CD8 + T cells (Fig. 3c,d and Supplementary Fig. 1e ,f). Using ad libitum (AL)-fed mice, which gain weight and visceral adipose tissue as they age, and age-matched calorie-restricted (CR) mice, we next determined whether limiting body weight and adipose tissue could minimize leptin levels and T cell exhaustion. CR mice had decreased visceral adiposity compared with AL mice, as measured by magnetic resonance imaging (Fig. 3e ), and weighed significantly less and had lower leptin levels ( Supplementary Fig. 8c,d ). The reduced obesity and leptin levels in CR mice were accompanied by a significantly lower frequency of PD-1 + CD8 + T cells in the liver and spleen as well as a lower frequency of Eomes+ PD-1 + CD8 + T cells ( Fig. 3f and Supplementary Fig. 8c -i), demonstrating that reduction of body fat resulted in lower leptin and T cell dysfunction with age. We next examined T cell phenotype in leptin-deficient ob/ob 30 and leptin receptor (ObR)-deficient db/db mice 31 , both of which are obese owing to lack of the satiety signal. As expected, db/db mice weighed significantly more than age-matched wild type (WT) control mice ( Supplementary Fig. 9a ), but the frequency of CD8 + T cells expressing PD-1 in db/db mice was significantly lower than that in WT control mice (Fig. 3g ). The ob/ob mice were weight-matched to wild-type DIO mice and were significantly heavier than WT control mice ( Supplementary Fig. 9b ). The frequency of CD8 + T cells expressing PD-1 from ob/ob mice trended lower than that of DIO mice with a similar weight but trended higher than that of control mice ( Supplementary Fig. 9c,d) . These results suggest that leptin is not required for PD-1 expression on CD8 + T cells but that in the setting of obesity intact leptin signaling contributes to the PD-1 + phenotype. We next examined the fate of T cells from WT (ObR + ) and db/db (ObR − ) mice on regular diet subject to allogeneic activation by adoptive transfer into immunodeficient but H2-disparate (H2 d ) NSG mice ( Supplementary Fig. 9e ). Comparing the number of CD8 + T cells originally transferred into NSG mice to the number of donor cells found in the spleen ( Supplementary Fig. 9f ) and liver ( Supplementary Fig. 9g ) at 13 days post transfer, we observed that WT cells expanded minimally in marked contrast with db/db T cells, which expanded robustly. This increased expansion of db/db CD8 + T cells was associated with lower PD-1 expression ( Fig. 3h,i) .
Comparing PD-1 frequency of transferred cells pre-and posttransfer, we found that both WT and db/db CD8 + T cells increased PD-1 expression upon transfer and chronic allogenic stimulation, but the extent of that increase was drastically more pronounced in WT CD8 + T cells, which showed a 40-fold increase in PD-1 expression ( Supplementary Fig. 9h ). These results suggest that T cells with intact leptin signaling are more susceptible to PD-1 upregulation and proliferative dysfunction with chronic stimulation in vivo, whereas leptin-unresponsive T cells remain functional with limited PD-1 upregulation.
To further link leptin to PD-1 expression and T cell exhaustion, we evaluated in vitro the effects of leptin on T cell activation directly. Mirroring the in vivo results with allogeneic stimulation, PD-1 expression on CD8 + T cells was increased upon stimulation with anti-CD3 (α CD3), and this upregulation was dramatically enhanced with addition of recombinant mouse leptin (rmleptin, Fig. 3j ). This increased PD-1 expression correlated with upregulation of phospho-STAT3 (pSTAT3; Supplementary Fig. 10a,b) , a major downstream mediator of leptin signaling, which is also known to induce PD-1 expression on T cells through distal regulatory elements that interact with the PD-1 gene promoter 32 . Importantly, the addition of a STAT3 inhibitor significantly decreased both the upregulation of pSTAT3 and PD-1 induced by stimulation and leptin ( Supplementary Fig. 10a-b ). Leptin can increase T cell activation 33, 34 and obesity can cause leptin resistance 35, 36 . An alternate explanation for the T cell phenotype of DIO mice could be that leptin increases T cell activation, and in obesity, T cells develop leptin resistance. Therefore, we examined the induction of pSTAT3 by leptin stimulation in T cells from control and DIO mice. There were no differences in the expression of pSTAT3 on CD8 + T cells from control and DIO mice ( Supplementary Fig. 10c ), indicating that CD8 + T cells in DIO mice are not resistant to leptin, in agreement with published reports on DIO mice. Our studies with sorted human T cells in vitro revealed that mitogen-driven proliferation of memory T cells, but not naive T cells, was inhibited by leptin, also in agreement with previous findings 37 ( Supplementary Fig. 10d ). Collectively, our findings implicate leptin as a link between obesity and increased PD-1 expression and exhaustion on memory T cells.
We then examined the effect of leptin on T cell exhaustion in tumor-bearing models using leptin-deficient mice. We treated B16-tumor-bearing ob/ob mice with rmleptin and examined tumor growth and immune activity ( Supplementary Fig. 11a ). Although ob/ob mice treated with exogenous rmleptin continuously lost weight, tumors in these mice grew faster ( Supplementary  Fig. 11b,c) . Importantly, leptin treatment resulted in increased CD8 + T cell exhaustion in the tumor environment with significantly decreased IFN-γ on PD-1 + CD8 + T cells (Fig. 4a ), increased numbers of PD-1 + CD8 + T cells, decreased expression of Ki67, and significantly increased expression of Eomes at the mRNA level ( Supplementary Fig. 11d-f ). Exogenous rmleptin also significantly affected CD8 + T cells outside of the TME as demonstrated in the liver. Leptin upregulated PD-1 expression at the mRNA and protein levels ( Supplementary Fig. 11g,h) , as well as mRNA expression of HAVCR2 (Tim3) and Cpt1a ( Supplementary Fig. 11i,j) , resulting in diminished proliferation of PD-1 + CD8 + T cells (Fig. 4b) . To examine the consequences of obesity and leptin signaling on the antitumor immune response, we adoptively transferred T cells from WT (ObR + ) or db/db mice into control or DIO immune-deficient C57BL/6 Rag2 -/mice, which lack T cells, bearing B16-F0 tumors (Fig. 4c,d and Supplementary Fig. 12a ). Consistent with our previous data, tumor growth was accelerated in DIO Rag2 -/mice compared with control Rag2 -/mice ( Supplementary Fig. 12b ,c) after adoptive transfer of WT T cells. Notably, tumor growth kinetics were similar regardless of whether db/db T cells were transferred into control or DIO Rag2 -/-C57BL/6 mice, whereas tumors grew faster in DIO Rag2 -/mice that received WT T cells than in control Rag2 -/mice that received WT T cells ( Fig. 4e and Supplementary  Fig. 12d ). This finding suggests that the obese environment, with elevated leptin, impairs the antitumor responses of transferred WT CD8 + T cells, but not leptin-resistant db/db CD8 + T cells. This is confirmed by TME immunophenotyping, which demonstrates significantly higher expression of PD-1 on WT adoptively transferred CD8 + T cells in DIO Rag2 -/mice versus db/db T cells in the DIO Rag2 -/mice or versus WT or db/db T cells in control Rag2 -/hosts ( Fig. 4f and Supplementary Fig. 12e ). Importantly, ex vivo analysis of TNF-α and IFN-γ production also demonstrated improved functionality of db/db TILs (compared with WT TILS) isolated from the TME of DIO Rag2 -/mice, whereas WT and db/db TILs from tumors in control Rag2 -/had equivalent functionality ( Fig. 4g-i and Supplementary Fig. 12f-h) . These results indicate a role of leptin signaling in increasing PD-1 expression and promoting T cell exhaustion in tumor-bearing mice, which affects antitumor immunity.
Improved efficacy of PD-1 checkpoint blockade in DIO mice.
Building on our observations that CD8 + T cells have increased exhaustion and dysfunction in obese, cancer-bearing subjects, we assessed the impact of PD-1 blockade on tumor growth. Administration of anti-PD-1 (α PD-1) as a monotherapy ( Supplementary Fig. 13a ) had minimal to no effect on control mice but surprisingly led to significant and marked reduction in B16 tumor burden and a significant improvement in survival in DIO mice (Fig. 5a,b and Supplementary  Fig. 13b,c) . Similar results were also observed in 3LL-tumorbearing DIO mice ( Fig. 5c and Supplementary Fig. 13d,e ). Of note, in agreement with our other models demonstrating accelerated tumor growth in obese models, 3LL tumors also grew faster in DIO mice. These results demonstrate that in models in which α PD-1 monotherapy has limited effect (B16) 38 or where there is some susceptibility to monotherapy (3LL) 39 , DIO mice displayed significantly greater therapeutic efficacy than control recipients. The improved responsiveness in DIO mice was associated with a significant increase in the total number of tumor-infiltrating T cells and increased frequency of CD8 + T cells in the TME (Fig. 5d,e and Supplementary Fig. 13f,g) , as well as an increased CD8-to-CD4 T cell ratio ( Supplementary Fig. 13h ) in response to therapy. In DIO mice, α PD-1 therapy also reduced the frequency of PD-1 + T cells in the TME ( Supplementary Fig. 13i,j) . Similarly, ex vivo functional assessment of splenic CD8 + T cells from α PD-1-treated tumorbearing DIO mice demonstrated significantly increased TNF-α 
Fig. 4 | Lack of leptin signaling rescues T cells from exhaustion in obese mice. a,
Frequency of IFN-γ + tumor-infiltrating CD8 + PD-1 + T cells after ex vivo stimulation (n = 3 per group, two technical replicates in ob/ob group, two to three technical replicates in ob/ob + rmleptin group). b, Frequency of Ki67 in CD8 + PD-1 + T cells in the liver of 3-month-old ob/ob male B16-F0-bearing mice treated with or without rmleptin (n = 3 per group). c, Schema showing C57BL/6 Rag2 -/mice challenged with B16 melanoma cells followed by adoptive transfer of T cells from either WT or db/db C57BL/6 mice. s.c., subcutaneous. d, Serum leptin levels of 5-month-old control and DIO C57BL/6 Rag2 -/male mice (n = 4 per group). Data in a,b,d are depicted as mean ± s.e.m., with all individual points shown. One-tailed unpaired Student's t-test was used to compare groups. e, Fold change of B16-F0 tumor growth in control and DIO Rag2 -/mice after adoptive transfer of T cells from either WT or db/db C57BL/6 mice (fold change compared to tumor size at time of adoptive transfer) (n = 2 per group). f, Frequency of PD-1 expression on tumor-infiltrating CD8 + T cells from B16-F0-bearing control (n = 4 in WT group, n = 5 in db/db group) and DIO (n = 5 in WT group, n = 4 in db/db group) Rag2 -/mice with adoptive transfer of T cells from either WT or db/db C57BL/6 mice. g-i, Representative flow staining (g) and frequency of IFN-γ -producing (h) and TNF-α -producing (i) tumor-infiltrating T cells after ex vivo stimulation collected from B16-F0-bearing control and DIO Rag2 -/mice with adoptive transfer of T cells from either WT or db/db mice (n = 2 per group, two or three technical replicates). Data in f,h,i, are depicted as mean ± s.e.m., with all individual points shown. One-way ANOVA with Tukey post-hoc test was used to compare groups. *P < 0.05, **P < 0.01, ****P < 0.0001. NS, not significant. and IFN-γ production on CD8 + T cells compared with controls ( Supplementary Fig. 14a,b) . Overall, α PD-1 therapy rescued CD8 + T cells from exhaustion and significantly improved survival in DIO mice. Similar antitumor effects were also observed in a melanoma metastasis model (B16-F10, Supplementary Fig. 14c ). Importantly, α PD-1 treatment significantly inhibited metastases in B16-bearing DIO mice, but not in control mice (Fig. 5f ). Further examination of the effects of α PD-1 in DIO mice revealed significant inhibition of both visceral and lung metastases ( Fig. 5g-j) . Importantly, despite the risks of severe or lethal toxicities after systemic immune-stimulatory therapies in obese mice 40 , adverse events were not observed after α PD-1 checkpoint blockade ( Supplementary Fig. 14d-g) , thus implying an uncoupling of heightened treatment response and risk of toxicity in the setting of obesity that may be contingent on the type of immunotherapy applied.
Impact of obesity on exhaustion and PD-1 checkpoint blockade
in patients with cancer. Because significant antitumor effects were observed with α PD-1 therapy in obese mouse models, we examined T cell phenotypes in the TME of obese patients with cancer. In a large cohort of 152 human colorectal cancers (CRC), we observed significantly fewer tumor-infiltrating T cells in obese patients (Fig. 6a,b ). Because patients with CRC have a poor response rate to checkpoint blockade, we also examined a more responsive tumor type: melanoma. In a cohort of 251 patients with melanoma with annotated clinical data from the cancer genome atlas (TCGA) a 1.57-fold (P = 0.019) increase in mean PD-1 expression was noted in tumors of obese patients (BMI ≥ 30) (data not shown). Among patients older than 60 years of age (n = 126), the effect of obesity on exhaustion marker expression in the TME was even more pronounced, with a threefold increase in PDCD1 (PD-1) in obese patients ( Fig. 6c , P = 3.2 × 10 −5 ), a twofold increase in HAVCR2 (Tim3) ( Fig. 6d , P = 2.0 × 10 −4 ), a threefold increase in LAG3 ( Fig. 6e , P = 2.0 × 10 −5 ), a 2.3-fold increase in TIGIT ( Fig. 6f , P = 1.3 × 10 −3 ), a 2.2-fold increase in TBX21 (T-bet) ( Fig. 6g , P = 9.0 × 10 −4 ), and a 1.79-fold increase in EOMES ( Fig. 6h , P = 6.9 × 10 −3 ). These results generally mirrored the TME phenotype in DIO mouse tumors, with no change in FOXP3, leptin receptor, CTLA-4, and CD274 (PD-L1) expression ( Supplementary Fig. 15a-d ). Most importantly, we observed a striking improvement in the clinical outcomes of obese (BMI ≥ 30) versus nonobese (BMI < 30) patients in a cohort of 250 human patients treated with α PD-(L)1 checkpoint blockade for a variety of cancers (Supplementary Table 2 ). There was a statistically significant improvement in progression-free survival (median: 237 d versus 141 d, P = 0.0034) and overall survival (median: 523 d versus 361 d, P = 0.0492) in obese patients (Fig. 6i,j) . As in obese mice, no increases in immune-related adverse effects were observed in obese patients (Supplementary Table 2 ). Using a Cox proportional hazards model to adjust for ECOG performance status, line of treatment, age, sex and cancer type, BMI category was still significantly associated with better progression-free survival (HR = 0.61, 95% CI = 0.42-0.89, P = 0.01) and overall survival after α PD-(L)1 therapy (HR = 0.594, 95% CI = 0.35-0.99, P = 0.048).
Discussion
In this report, we demonstrate for the first time to our knowledge, across multiple species and tumor models, that obesity increases T cell aging resulting in higher PD-1 expression and dysfunction, which is driven, at least in part, by leptin signaling. We also observed increased tumor progression in the setting of obesity, and this was probably due to immunosuppression as well as direct (metabolic and hormonal 41 ) effects. However, the PD-1-mediated T cell dysfunction in obesity remarkably left tumors markedly more responsive to checkpoint blockade. Importantly, these preclinical findings are corroborated by clinical data demonstrating significantly improved outcomes in obese patients with cancer treated with PD-1/PD-L1 inhibitors. Our findings validate and provide a mechanism for a recent report in obese patients with melanoma showing improved outcomes with immunotherapy 14 . In that study, the effect was limited to male patients with melanoma, whereas our clinical data extend across cancer types and demonstrate a positive effect even when controlling for sex. Although our study focuses on PD-1-mediated T cell dysfunction induced by obesity, sex and other factors such as age, genetics, metabolic dysregulation, gut microbiome, dietary differences and the duration of obesity probably confound the effects of obesity on the immune system and warrant further study. Age in particular is known to increase the memory pool of T cells and may be a key confounder, particularly in specific-pathogen-free laboratory mice, which experience limited exposure to immune challenges. In our studies, 6-month-old DIO mice did not display the heightened phenotypic exhaustion seen in 11-month-old DIO mice, unless challenged with a tumor. This finding is consistent with the concept that obesity results in an immune aging effect, termed inflammaging 12 , which is accentuated by immune challenge. Thus, age, sex, exposure to immune challenge and obesity may all play critical roles in shaping immune responses. Furthermore, obesity probably operates via multiple pathways aside from the PD-(L)1 axis to induce T cell dysfunction and promote tumor growth, and these phenomena are likely also influenced by diet. We observed elevated Cpt1a expression, a master regulator of fatty acid oxidation and driver of metabolic changes leading to exhaustion 18 . Other factors associated with obesity, such as free fatty acids, insulin/ IGF1, and proinflammatory cytokines such as TNF and IL-6, all are likely to contribute to this phenotype outside of body fat. As a result, it will be important to ascertain the effects of different diets and duration of exposure needed to observe possible immunealtering effects.
In our study, tumor-bearing DIO mice showed higher expression of Eomes than T-bet, which supports an exhausted CD8 + T cell profile 4, 42 . Although some studies suggest that T-bet hi but not Eomes hi exhausted T cells respond better to PD-1 blockade 4 , it has been demonstrated that blocking the PD-(L)1 axis can reinvigorate PD-1 hi T-bet lo Eomes + CD8 + T cells 43 .
We focused on leptin as a mechanism of obesity-induced T cell dysfunction, given that STAT3, a major downstream transcription factor of the leptin receptor 44, 45 , has known binding sites in the promoter region of PD-1 46, 47 and has been implicated in driving expression of PD-1 in human and murine cancers 48 . However, it is important to recognize that these molecules have broad pleiotropic effects, and other pathways are probably implicated. This notion was demonstrated by the effects of administering leptin to ob/ob mice, where significant metabolic effects also occurred.
While leptin has been well documented to impact T cells, particularly T reg s, the literature also suggests that leptin increases T cell activation 26, 34 , which may be explained by the opposing effects of leptin on naive versus memory T cell populations as previously reported 37 . PD-1 plays critical roles both in early T cell activation as well as in later chronic stimulation, where the exhaustion phenotype predominates. Thus, differences between our findings and others are likely to be explained by the T cell populations examined and the time points assessed. The impact of leptin and obesity on other immune cells is also likely to be important, given the recent report linking leptin in tumor-bearing DIO mice with PD-L1 expression in myeloid-derived suppressor cells 49 . Our results also suggest that targeting the leptin receptor on activated T cells or CAR T cells in immunotherapy may be of use to augment T cell function, particularly in high-leptin circumstances.
Overall, our data suggest that obesity-associated inflammaging results in increased T cell aging and induction of normal suppressive pathways to counter this chronic inflammatory state. In obesity, PD-1-mediated immune suppression may be a mechanism to protect against possible autoreactive or hyperactive T cell responses induced by chronic inflammation. Importantly, the linkage of obesity and leptin to PD-1 and T cell dysfunction in cancer progression appears remarkably robust in both mouse and human studies. It remains to be determined whether obesity increases PD-1 + CD8 T cells in a broad range of human cancers and whether this mechanism also contributes to the increased incidence of cancer in obese patients. Furthermore, it remains to be delineated clinically whether the environment in the obese state results in greater T cell activation and function once checkpoint blockade is applied. It is unclear whether obesity may impact the survival of patients with cancer by other nonimmune factors as well. In that regard, obesity should not necessarily be regarded as a positive prognostic factor in cancer but rather as a potential mediator of immune dysfunction and tumor progression that can be successfully reversed by PD-(L)1 checkpoint inhibition resulting in heightened efficacy.
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